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BeveraAcuteHeartFellure
D. Pellerin, P.Demolis, J.L. Teboul, C. Veyrat, A. Berdeaux, J.F. Giudicelli,
S. Witchitz. The University Heap/ta/of Blcetre, La Kremlin Bicetra, France
Since Iinaidomine (L) isadirect nitric oxide donor it may not induce tolerance.
To evaluate the effects of L on cardiac and brachial hemcdynamics and the
development of L tolerance during a 46-hour period, 10 patients (62 +
10 yrs) with dilated cardiomyopathy and acute heatt failure received step
increaae doses of L (0.5 r.@kg/min) started > 4 hours after insertion of
the pulmonary artery catheter without any other drug. The maximal dose
of L was defined as the lowest of the 2 incremented doses responsible
for a mean pulmonaty artery wedge pressure (MPWP) or a cardiac index
(Cl) change Ie.sathan 10% or for a mean blood presaure (MBP) below 60
mmHg. Restdk: At the maximal dose of L (2.3 + 1.3 @k@mln, range 0.5-5
wYl@mln) all parameters but heart rate changed significantly from baseilne.
Cl was 2.44 + 0.61 I/mIn/m* from 1.5 + 0.3, MBP 69,+ 6 mmHg from83
+ 9, Systemicvascularresistance(SVR) 2141 + 448 dynes.s.cm-s from
3719 + 1058, MPWP 17 + 9 mmHg from 30 + 8, Right atrial pressure
(RAP) S + S mmHg from 16&8, Pulmonary vascular resistance 381 + 13
dynes.s.cm-5 from 661 + 326, Pulmonary artery saturation 56.8 + 9.6%
from 45.9 + 10.5, Brachial atiery diameter 4.5 + 0.3 mm from 4.1 + 0.1,
Brachial artery blood flow 107.5+ 35.6 mUmlnfrom 75.7+ 31.3 (2D pulsed
Doppler system). At the maximal dose of L, the study was stopped in 3
patients dueto headacheor noimprovementin Cl andMPWP. In 7 patients
the maximal dose of L was continuously infuaed and ikeeffects persisted for
24 hours, Ltolersnce developed in 2 patients (after 25 and 34 hour infusions
mspestively) characterizedbyincreased dyepnea, MPWP and RAP despite
small decreaseIn Cl and SVR. Corrcluskrrr:L improves cardiac and brachial
hernodynamiosInpatients wlthsevere acute haartfailura. However tolerance
to maintained high doses of L may develop in some patients after 24 hours.
m1084148 BeneflolalAcuteHemodynamlcEffeotofEndoaenousAdenosineAccumulationin
Patie;~ withChronicHeertFailure
L. Cortigiani, M. Baroni, E. Picano, C. Palmierf, M. Ravani, A. Boni,
E. Nannini, A. Biagini. Cardiovascular Unit, Castelnuovo Qarfagnana
Hospital, Lucca, Italy CNR Institute of Clinical Phyalo@rK Plea, Italy
Exogenouely administered adenosine reduces vascular resistance and in-
creaeee cardiac output in normal subjects end in patients with pulmonary
hypertension orend-etage biventricular heart feilure. Endogenous adenosine
accumulation can be provoked by dipyridamole (DIP). The aim of the study
wee to assess the acute effects of endogenous adenosine accumulation in-
duced by an infra-low dose (0.28 mg/Kg over 4’) DIP infusion on systemic
and pulmonary hemodynamics in patients with severe chronic heart failure.
Twenty patiente (11 men and 9 women, mean age ~ & 8 years) with chronic
heart failure (mean ejection fraction 25 + 5%) underwent right hearicatheter-
ization. Hemodynamic variables were meesurad before end after infra-low
dose DIP infusion. After DIP there was a mild increase in heart rate (rest =78
+ 18ve DIP= 81 + 14 bpm, p= 0.03) and reduction in mean systemic blood
pressure (rest =98 & 17ve DIP= 91 l 16 mm Hg, p < 0.001). DiP increased
cardiac output (rest =4.5 & 1 vs DIP 5.7+ 1.3 Vmin,p < 0.001) and cardiac
index (rest= 2.5 &O.6ve DIP= 3.1 +0.7 l/mirdm2,p e 0.001), and decreased
syatemic vascular resistance (rest= 30 + 11.8vs DIP = 22.6+ 9.8 Wads
unit, p < 0.001). Moreover, DIP reduced mean pulmonaty artery pressure
(rest =31 +12 vs DIP= 28 + 13 mm Hg, p < 0.01) and pulmonary vascular
resistance (rest = 4.3 + 2.6 vs DIP = 2.9 + 2.1 Woods unit, p c 0.001),
without changes in mean pulmonary wedge preasure (rest = 20 + 9 vs DIP
=18 + 10 mm Hg, p = NS). There was a significant correlation between per-
cent decrease from baseline in pulmonary and systemic vascular resistance
(r= 0.68; p = 0.002) after DIP. Acute endogenous adenoaine accumulation
induced by infra-low doee DIP improves the hemodynamic profile decreasing
pulmonary and vascular resistance and increasing cardiec index in patients
with severe chronic heert failure.
a108538 AbnormalCardiacFibroblastaUnmeakedByVesnarinone:A PossibieContributorto Heart
FaiiureinAorticRegurgitation
J.S. Ross, S.M. Goldfine, E.M. Herrold, J.S. Borer. The New York Hosp/ra/,
Come\l Madical Centec New York,NX USA
We have previously shown that, in experimental aortlc regurgitation (AR),
congestive heart failure (CHF) and death are preceded by exfenslve fibrob-
Iast (F)-mediatad primary fibrosis. Vesnarinone (VS) Is a K+ channel blocker
which 1) may reduce CHF hospitalizations and mortality and 2) affects F
morphology. To determine if VS may act In part by suppressing myocar-
dial fibrosis, we examined VS effects on cardiac F in culture. Cells were
enzymatically isolated from adult New Zealand White rabbits with anrJwith-
out surgically-induced severe chronic compensated AR and cultured for up
to 8 passages. Cultures were treated with sulfolane-solubilized VS (con-
centrations = 1 x 10-5M to 1 x IO-g M). F morphology and number were
assessed from normal (12 experiments) and AR (7 experiments) cultures;
various doses were tested in each experiment. No effect on F morphology
was seen et any concentradon. However, at 5 x 10-7M VS, normal F cell
number was 55% less than sulfolane cantrol (p= 0.03); at higher doses, cell
number Increased, peaking slightly above control. In contrast, in AR cells,
mmparable reductions (p < 0.02) were seen at low concentrations (down to
1 x 1O-SM);however,cell number increased but did not reach ~ntrol value,
even up to 1 x 10-5M. In situ labeling (3 experiments) suggest VS acts via
induction of apoptoais aince 5 x 10–7MVS-treatad cultures contained twioe
as many apoptotic cells as controls (p s 0.1). Thus, chronic AR alters F
biology, possibly contributing to CHF. Suppression of fibrosis by diminishing
F viability maybe partly responsible to clinical benefit of VS in chronic CHF.
[1085-39/ Aofti~R~urgitationis FraquentlyPreaentin
PatientsWithFamilialHyperchoiesterolemia
S. Mittal, J.S. Cohen, B.J. Clark, D.J. Rader, J.M. Wileon, S.E. Wiegere,
D.M. Kolansky. The Hospita/ofthe University of Pennsylvania, Phi/ade/phia,.
PA, USA
Familial hypercholesterolemia (FH) causes earfy atherosclerosis of theaonic
root (AoR) and aortic valve (AV) and extends into the origin of the coronary
arteries. We ‘aimed to define the spectrum of AoR and AV abnormalities in
these patients (pte).
Methods: We evaluated 32 pts with FH, age 3 to 45 years; 19 were
malea and 13 females. Mean cholesterol level was 560 mgldl (270-1082
mg/dl). Cardiac catheterization (with cartography) and/or echocardiography
was pettormed in 28 pts. Aortic regurgitation (AR) and stenosis (AS) were
graded in standerd fashion.
Results: A left ventricle to aorta gradient of 10-75 mmHg, predominantly
aupravelvular,was preaent in 8 (28%) pta. AR was present in 16 (57%) pts;
of these pts, 56% had at least moderate AR. A thickened AV, usually at the
ieaffet tips, was visualized in 78% of pts who underwent echocardiogrephy.
SO”+&of pta with AR had concomitant AoR disease, characterized by an
irregular, narrowed, thickened and calcified proximal aorta. AR was eeen
as a central andbr eccentric jet and appeared related to incomplete AV
coaptetion due to atheromatous deposition in the AoR and/or AV leaflets.
There was no association between age and the eeverify of AVabnormalitiea.
Moderate AR wee present even in the firat decade of life.
Conclusions: AR is the meet common AV abnormality in pts with FH. Pte
with FH should,be promptly screened for AR and eeriai evaluations of the AV
should be patformed when AR is present.
11085-40[ piaSmaAtria,NatriUreticpe@ideandBrain
NatriureticPeptideLevelsinChronicAortic
Regurgitation
J. Kanda, M. Suzuki, N. Takeuchi, K. Nakamura. Asahi Geners/Haspita/,
Aaahi, Japan
The purpose of this atudy was to estimate the value of the measurement of
plasma atrial natriuretic peptide (ANP) and brsin natriuretic peptide (BNP)
levels in chronic aortic regurgitation (AR). We measured plasma ANP and
BNP Ievals in 15 patients (pte) with chronic severe AR accompanied with
left ventricular dilatation. The pts were divided into two groups depending
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on the presence of symptoms (group A: 8 asymptomatic pts and group
S: 7 symptomatic pts). We compared pulse pressure, cerdiothoracic ratio
(CTR), echocardiographic variables (LVDd, LVDS, FS, LAD), plasma ANP
and BNP levels between the two groups. The plasma ANP and BNP levels
were significantly higher in group S than in group A (107.1 + 35.6 vs. 21.4
& 10.8 p~ml, p <0.05, and 356.0 + 172.2 vs. 56,5 + 34.8 pglml, p <
0.05, respectively). In group A, only one patient showad an abnormal high
level of ANP (> 40 p~ml) while all pts showed abnormal high level of BNP
(> 20 pglml). On the other hand, all pts in group S showed abnormal high
levels of both ANP and BNP. And pulse pressure, CTR, LVDd, and LVDS
in group S were significantly increased than those in group A. Pulmonary
capilla~ wedge pressure and left ventricular end-diastolic pressure were
also elevated in 4 of 5 symptomatic pts performed cardiac catheterization.
These findings suggest that the elevated plaama ANP level indicates the
decompensated state of Ieftventricle and that plasma BNP level is increased
not only in symptomatic pts but also in asymptomatic pts with chronic AR
according to its severity. Conclusion: The measurement of plasma ANP and
BNP levels is practical in the evaluation of chronic AR.
I 1085-41] Pl*smaLevelS~fAd~nome~u,,in(A~)~~~~e,a*e
withthe Extentof PulmonaryHypertensionin
PatientewithMitralstenosis(MS)
T. Nishikimi, S. Nagata, T. Sasaki, K. Kimura, S. Tomimoto, A. Miyate,
K. Kangawa, H. Matsuo, H. Matsuoka, S. Takishita. National Cardiovascular
Centec Osaka, Japan
AM reduces the blood pressure, pulmonary vascular resistance, and in-
creases pulmonary blood flow. Recent reports showed that AM mRNA and
and AM receptor mRNA is strongly expreased in the lung. To determine
the pathophysiological aignificence of AM in the pulmonary circulation, we
investigated the relationship between plasma levels of AM and pulmonary
hypertension in patients with MS. Plasma levels of AM in blood samples ob-
tained from the vein, pulmonaty artery, left atrium, and aorta were measured
by RIAin 23conaecutive patients with MS (53 + 10yrs)who were undergoing
percutaneous mitral commissurotomy. Patienta with MS had higher venous
plasma levels of AM than age-matched normal controls (3.9+ 0.3 vs. 2.5+
0,3 pmol/L, p < 0.01). There was a reduction of plasma AM levels from the
pulmonary artety to the left atrium (3.8+ 0.2 vs. 3.2+ 0.4, p < 0.01). These
levels significantly correlated with mean pulmonary artery pressure, total pul-
monary vascular resistance, and pulmonaty vascular resistance (r = 0.65, r =
0.63, r= 0.65, eech p < 0.01). Multiple regressionanalysis revealedthat total
pulmonaty vascular resistance independently mrrelated with plasma levels
of AM (p < 0.01). Given that the vascular wall mainly produces AM, and that
AM specific receptors exiat on the smooth muscle cella, and that AM acta on
the pulmonary vascular bed, increaaed plaama AM in patients with MS may
help to prevent the increase in pulmonary arterial resiatence in secondary
pulmonary hypertension.
m108542 “NeturelHistories”of MitralValveProlapse
A. Zuppiroli, F. Mori, S. Favilli, F. Pleri, V. Troiani, M. Bini, A. Dolara,
M.J. Roman M.J. O’Gradyl, R.B. Devereuxl. U.O. Cardiobgia 2,
Ospedale Careggij Fhrze, Ita& 1Cornell Medicai College, New York,NY
USA
The prognoais of mitral valve prolapse (MVP) remains uncertain, as previous
longitudinal studies of patienta (pts) with MVPgiveeatimatesof the incidence
of complications from 0.3 to 3.7/100 patient-years (p-yre). Between January
1979 and August 1996 a total of 263 pts, aged 43 + 19 yeare, 140 (53%)
women were followed for a mean of 96 months in a referral center for
valvularheart diseaaea.During the follow-up periodatotal of 63mmplications
occurred (3.0/100 p-yre): 46 pts (2.2/10Qp-yre) required mitral aurgery, 10
auffered cardiac death (0.5/100 p-yrs), 6 developed necrologic ischemia
(0.3/100 p-yrs) and 1 developed infective endocarditis (0.04/100 p-yrs). The
overall rate of complications varied aignificently (all p < 0.0001) in relation
to demographic, clinical and echocerdiographic variables, being higher in
men (odds ratio [OR] = 2.0), in subjects ? 45 yrs (OR = 9.5), in those with
a holosyatolic murmur (OR = 25.4), in those with enlarged (Z 60 mm) left
ventricle (OR = 12,5) or left atrium (z 40 mm) (OR = 29.2), in those with
a grade 3 or 4 mitral regurgitation (OR = 33.6) and lower in those with an
audible midsystolic click (OR = 0.07). This rate of complications far exceeds
the 1/100 p-yre we previously reported in a series of relatively unselected
pts or family members in New York, but predictors of complications are quite
eimilar. Therefore it ia confirmed that in a common entity like MVP tettiary
csrecenters mainly seethe most affected individuals: this selection bias adds
to male gender, older age and markers of mitral regurgitation in predicting an
adverse “natural hiatory” of MVP.
-] ~,iniCalSUfXtratesfOrt.chJcib,e~onomorf)hicVT
AmongPatientswithValvularHeartDisease
C, Narasimhan, Z. Blanck, S. Deshpande, A. Rehman, M.R. Jezayen,
J. Sra, M. Akhtar. Sinai Sanraritan/St. Luke’s Medica/ Centers, Mi/waukee,
Wl, USA
There is very Iittledata on theelectmphysiologic mechanisms and subatratea
for ventricular techycerdia (VT) among petienta with valvular heart diaease.
We analyzed the mechanism of inducible sustained monomorphic VT in pta
with valvular hearl disease. There were 27 pts (23 men, 4 women) age 60
+ 15 yrs. in 10 of the 27 pts sustainad bundle branch reentty (BBR) was
the only mechanism of VT and 17 pts had intramyocardial VT (MVT). Both
groups were compared.
BBR (10) MVT (17) P VALUE
1. Age 5s * 19 60+ 1S ns
2. Cardiac Arrest 4 5 ns
3, Syncopelpresyncope 3 s ns
4. CAD 2 9 ns
5. EF > 55”/Q 4/10 1/17 <0.05
6. HV Interval (ins) 65& 15 56* 14 <0.01
Conclusion: In pts with valvular heart diaease: 1) Sustained BBR is the
mechanism of VT in approximately a third of the pts with inducible auateined
VT, 2) LV function was better preserved among pte with BBR compared to
MVT,and 3) HV interval is significantly prolonged in pts with BBR compared
to MVT.
11085-44IMitral-Valv~Prolap*inMilitiwMem@rs:
Long-termFollow-upandClinicalRiskAnalysis
S.S. Osswald, F.A.Gaffney, J.C. Hardy,W.G. Jackson. Brooks A/rForce
Base, San Antonio, TX, USA
The natural history of mitral valve prolapse (MVP) was assesaed in 404 pre-
dominantly male, largely asymptomatic military members. Individuals had
auscultatory MVP by two cardiologists and/or echocerdiographic MVP by 2-
D imaging. There were 395 (98%) men and 9 (2%) women. Aaymptomatic
individuals discovered by routine screening numbered 161 (40%), whereas
243 (600A)were cardiovascular (CV) referrals. The ages ranged from 21 to
64years (mean =36 years). Follow-up time averaged 8.6 years (1-21 yeara).
During follow-up, 5 patients died, 3from non-cardiac causes, 5required mitral
valve surgery, 4 experienced cerebral iechemic events, 7 progressed to se-
vere MR, 10 had epiaodes of atrial fibrillation, and 8 had SVT greater than 15
seconds. There were no episodes of endoearditis or ventricular techycerdia
(> 15sec). SBEprophylexis was reported in77%of individualabysurvey. The
overall rate of significant complications was 0.92%/year. Stepwise Icgiatic re-
gression seleeted left ventricular enlargement (LVE) >6 cm (adjusted cdda
ratio (OR) = 7.7, p < 0.001), left atrial enlargement (LAE) >4 cm (adjuated
OR=4.3, p= O.004),and age> 45 yeara (adjueted OR= 3.2, P= O.015)to be
significant predictors of complications. in univariate analysia, additional rkk
factors of mitral valve thickening with prolapse and CVreferrala both hadodda
ratios significant top <0.05. Conclusion: The riak of complications with MVP
in an asymptomatic, male population is low. Significant risk factors include
LVE, IAE, and age >45 years Risks also appear higher for thoee referred
for CV diagnosis and those with both mitral valve thickening and MVP on
echocerdiogram. Auscultatory MVP was not a significant risk factor.
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